Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT05112536 |
| Title | Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer |
| Recruitment | Active, not recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | No |
| Sponsors | G1 Therapeutics, Inc. |
| Indications | |
| Therapies |
Cyclophosphamide + Doxorubicin + Pembrolizumab + Trilaciclib |
| Age Groups: | senior | adult |
| Covered Countries | USA |